SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIBs recent price uptick and attempts to break through resistance are driving speculation about a renewed meme-coin rally, with traders watching for a breakout. The community is split between accumulation and bullish hopes for a pump and frustration over prolonged sideways trading, weak utility, and limited token burns.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is drawing attention for a breakout to fresh highs, with traders highlighting strong momentum and the appeal of its dividend-paying, defensive healthcare profile. Positive pipeline developmentsincluding Parkinsons drug approval and encouraging lymphoma trial resultsalso feature in the bullish discussion, alongside speculative talk about AbbVie as a potential biotech acquirer.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Bullish discussion centers on Injectives tokenomics and ecosystem, especially a live governance proposal that traders say could double INJs deflation rate, alongside RWA development and ETF interest. Supporters call the token undervalued and favor accumulating or staking, while skeptics point to its prolonged downtrend and question whether the fundamentals will lift its price.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMP is drawing attention on bullish breakout setups, with traders citing chart patterns and its capped token supply. Optimism about Compounds institutional-market push and V4 roadmap is tempered by complaints that the token has lagged other crypto assets.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canadas sharp selloff and underperformance versus U.S. airline peers dominate discussion, with traders speculating that shares tendered but not repurchased in the substantial issuer bid, short pressure and elevated fuel costs are weighing on the stock. Bulls see the decline as an opportunity and point to remaining buybacks and Aeroplans value, while bears warn of further downside and earnings risk.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubriks rally toward fresh 52-week highs is driving attention, with bulls pointing to strong momentum and continued demand for its data-protection and cybersecurity platform. Bears counter that the stock is richly valued and may lag cybersecurity peers, while some traders are taking profits or betting on a pullback.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Repeated revenue and guidance misses, alongside uncertainty over VEVYEs pricing and ability to turn prescription growth into revenue, are driving the negative discussion. Long-term bulls point to VEVYE, IHEEZO and Harrows broader ophthalmic portfolio, while skeptics say management must show more consistent execution before the growth thesis is credible.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynex is drawing attention amid a sharp mortgage-REIT selloff tied to rising Treasury yields and rate concerns, which traders say can pressure mortgage-backed securities and book value. Some are buying the dip for the monthly dividend and viewing the decline as overdone, while others remain wary of further losses and dividend risk.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Takeover chatter tied to reported Lundbeck interest is driving attention, though Xeris has said it is not for sale and no deal is confirmed. Traders speculate about other bidders and a possible bidding war, while skeptics question the rumor and point to Recorlev growth and the XP-8121 pipeline as the longer-term investment case.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCYs range-bound price action and ongoing share buyback dominate the discussion, with traders debating whether repurchases are supporting the stock or keeping it pinned. Bulls point to Luckins store growth, international expansion and a possible U.S. relisting, while skeptics cite the OTC listing, China-related risks and weak price momentum; a relisting timeline remains speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Invesco Dow Jones Industrial Average Dividend ETF (DJD) Be on Your Investing Radar?

Nike Stock Slips Premarket: Retail Calls Nike A 'Sinking Ship' After S&P 100 Exclusion 

Equity

Retail sentiment remains bearish as traders criticize Nike’s weak performance, stale products, and uncertain turnaround under CEO Elliott Hill. 


Nike’s Turnaround Gets Fresh Vote Of Confidence From Dick’s: Is NKE Stock A Buy-The-Dip Opportunity?

Dick’s Sporting Goods praised strong demand for Nike performance footwear.


NKE Stock In Focus: $10K Invested In Nike A Decade Ago Would Have Lost Money Despite Pandemic-Era Surge 

Weak China sales, sluggish Nike Direct performance and intensifying competition continue to weigh on sentiment. 


NKE Vs LULU: Retail Traders See A Bigger Comeback Opportunity In One Stock

Nike and Lululemon face challenges as both brands struggle with weaker demand, strategic shifts, and steep stock declines.


Is Invesco Dow Jones Industrial Average Dividend ETF (DJD) a Strong ETF Right Now?

NKE Stock Trails S&P 500 By Widest Margin In 25 Years – Can Elliott Hill’s Turnaround Effort Change Narrative?

Nike is struggling after a twenty-five-year market underperformance caused by strategic missteps, weak product innovation, and China challenges. 


NKE Stock Faces Second Weekly Loss: Nike Takes Greater Control Of China Sales, Resets Digital Strategy 

Nike will revamp its China business by focusing on online sales through official channels.


NKE Stock Eyes Weekly Gain: Analysts Still See Upside As Turnaround Debate Intensifies 

Wall Street backs Nike’s business recovery despite near-term challenges. 


Invesco Exchange-Traded Fund Trust - Invesco Dow Jones Industrial Average Dividend ETF

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$63.78
Prev Close	$63.44
Open	$63.36
Dividend Yield	N/A
50-Day Moving Average	$64.95
Beta	N/A
Avg. Volume	44,131.10
PE Ratio	N/A

52-Week High	$66.83
52-Week Low	$54.03
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

DJD Fundamentals